

**Title of Trial:** Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of the European Observational Safety Study 25878 (CLEAREST™)

**Investigational Product:** efalizumab

**Trial No.:** 27577

**Study Centers:** Not available

**Trial Initiation Date:** 11 Jun 2008

**Trial Completion Date:** 31 Jul 2009

**Development Phase:** Phase 4

**Publication (reference):** None

**Study Objectives:** Data not available

**Methodology:** Data not available

**Number of Subjects (Planned and Analyzed):** Data not available

**Diagnosis and Main Criteria for Inclusion/Exclusion:** Data not available

**Study Treatment:** Data not available

**Criteria for Evaluation:** Data not available

**Statistical Methods:** Data not available

**Results:** Data not available

**Conclusions:** Data not available

Due diligence was done and all potential information sources have been exhausted. No source documents for this study were identified. Due to non-availability of clinical study reports and synopses, results were not posted in EudraCT database

**Merck KGaA**

These results are supplied for informational purposes only.